Top Markets
#1 TENDIES TENDIES +42.62%
#2 Cash Cat Cash Cat +27.92%
#3 ICON ICON +23.59%
#4 Asteroid Shiba Asteroid Shiba +17.29%
#5 OSK OSK +15.36%
#6 MarsCoin MarsCoin +13.78%
#7 Threshold Network Threshold Network +12.29%
#8 龙虾 (Lobster) 龙虾 (Lobster) +10.00%
#9 Tornado Cash Tornado Cash +9.69%
#10 Kite Kite +9.57%
Coin of the day
TENDIES TENDIES
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Classement en actions #16730
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Prix de l'action
$3.78
Dernière synchronisation: 2026-03-17
Capitalisation boursière
$276.54M
Changement (1 jour)
0.00%
Changement (1 an)
45.53%
Pays
CA
Échange NervGen Pharma Corp. (NGEN)

Catégorie

Healthcare
Bénéfices pour NervGen Pharma Corp. (NGEN)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de NervGen Pharma Corp., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour NervGen Pharma Corp. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH